1. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein.
- Author
-
Zhang Y, Zhang Y, Xia L, Zhang X, Ding X, Yan F, and Wu F
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Azurin genetics, Azurin therapeutic use, Cell Line, Tumor, Disease Models, Animal, Female, Genetic Engineering, Lung Neoplasms prevention & control, Lung Neoplasms secondary, Mammary Neoplasms, Experimental metabolism, Mammary Neoplasms, Experimental microbiology, Melanoma, Experimental metabolism, Melanoma, Experimental microbiology, Mice, Mice, Inbred BALB C, Plasmids, Azurin biosynthesis, Drug Delivery Systems, Escherichia coli classification, Escherichia coli genetics, Escherichia coli metabolism, Mammary Neoplasms, Experimental therapy, Melanoma, Experimental therapy
- Abstract
Many studies have demonstrated that intravenously administered bacteria can target and proliferate in solid tumors and then quickly be released from other organs. Here, we employed the tumor-targeting property of Escherichia coli Nissle 1917 to inhibit mouse B16 melanoma and 4T1 breast tumors through the expression of azurin protein. For this purpose, recombinant azurin-expressing E. coli Nissle 1917 was developed. The levels of in vitro and in vivo azurin secretion in the engineered bacterium were determined by immunochemistry. Our results demonstrated that B16 melanoma and orthotopic 4T1 breast tumor growth were remarkably restrained and pulmonary metastasis was prevented in immunocompetent mice. It is worth noting that this therapeutic effect partially resulted from the antitumor activity of neutrophils and lymphocytes due to inflammatory responses caused by bacterial infections. No toxicity was observed in the animal during the experiments. This study indicates that E. coli Nissle 1917 could be a potential carrier to deliver antitumor drugs effectively for cancer therapy.
- Published
- 2012
- Full Text
- View/download PDF